RGNX · NASDAQ
REGENXBIO (RGNX) Stock Price & Fundamentals
REGENXBIO (RGNX) closed at $665.96 on Oct 9, 2026, up 1.81% from the previous close of $654.11.
Share price, past year
1Y +19.19%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $665.96 |
| Sep 30, 2026 | $649.31 |
| Aug 31, 2026 | $636.33 |
| Jul 31, 2026 | $646.34 |
| Jun 30, 2026 | $635.83 |
| May 29, 2026 | $631.47 |
| Apr 30, 2026 | $609.87 |
| Mar 31, 2026 | $627.36 |
| Feb 27, 2026 | $610.76 |
| Jan 30, 2026 | $576.84 |
| Dec 31, 2025 | $540.53 |
| Nov 28, 2025 | $560.49 |
| Oct 31, 2025 | $553.84 |
Key statistics
- Market cap
- $36.07B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.79
- Revenue (TTM)
- $174.48M
- Net income (TTM)
- −$196.43M
- Shares outstanding
- 54.2M
- Dividend yield
- —
- 52-week range
- $532.36 – $665.96
REGENXBIO's market cap is $36.07B, based on a share price of $665.96 and 54.2M shares outstanding as of Jun 30, 2026.
Financials
REGENXBIO reported revenue of $170.44M for fiscal 2025, up 104.54% from fiscal 2024.
REGENXBIO reported a net loss of $193.88M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $170.44M | +104.5% | −$193.88M | −113.8% | −$3.76 | −$126.38M |
| FY2024ended Dec 31, 2024 | $83.33M | −7.7% | −$227.10M | −272.5% | −$4.59 | −$175.56M |
| FY2023ended Dec 31, 2023 | $90.24M | −19.9% | −$263.49M | −292.0% | −$6.02 | −$228.37M |
| FY2022ended Dec 31, 2022 | $112.72M | −76.0% | −$280.32M | −248.7% | −$6.50 | −$238.21M |
| FY2021ended Dec 31, 2021 | $470.35M | +204.3% | $127.84M | 27.2% | $2.91 | $134.70M |
| FY2020ended Dec 31, 2020 | $154.57M | +338.7% | −$111.25M | −72.0% | −$2.98 | −$80.93M |
| FY2019ended Dec 31, 2019 | $35.23M | −83.9% | −$94.73M | −268.9% | −$2.58 | −$119.43M |
| FY2018ended Dec 31, 2018 | $218.51M | +2,002.4% | $99.94M | 45.7% | $2.73 | $91.37M |
| FY2017ended Dec 31, 2017 | $10.39M | +126.5% | −$73.17M | −704.0% | −$2.45 | −$65.15M |
| FY2016ended Dec 31, 2016 | $4.59M | — | −$62.97M | −1,372.1% | −$2.38 | −$56.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $108.02M | $22.71M | $0.43 |
| Q1 FY2026ended Mar 31, 2026 | $6.39M | −$90.05M | −$1.72 |
| Q4 FY2025ended Dec 31, 2025 | $30.34M | −$67.15M | −$1.30 |
| Q3 FY2025ended Sep 30, 2025 | $29.73M | −$61.94M | −$1.20 |
| Q2 FY2025ended Jun 30, 2025 | $21.36M | −$70.87M | −$1.38 |
| Q1 FY2025ended Mar 31, 2025 | $89.01M | $6.08M | $0.12 |
| Q4 FY2024ended Dec 31, 2024 | $21.21M | −$51.19M | −$0.99 |
| Q3 FY2024ended Sep 30, 2024 | $24.20M | −$59.60M | −$1.17 |
Company profile
- Name
- REGENXBIO Inc.
- Ticker
- RGNX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 9804 Medical Center Drive, Rockville, MD 20850
- Fiscal year ends
- December
- SEC CIK
- 0001590877
Recent SEC filings
- Sep 23, 2026
- Aug 25, 2026
- Aug 24, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 20, 2026
- Jun 29, 2026
- Jun 3, 2026
Frequently asked questions
What is REGENXBIO's stock price?
REGENXBIO (RGNX) closed at $665.96 on Oct 9, 2026, up 1.81% from the previous close of $654.11.
What is REGENXBIO's market cap?
REGENXBIO's market cap is $36.07B, based on a share price of $665.96 and 54.2M shares outstanding as of Jun 30, 2026.
How much revenue does REGENXBIO make?
REGENXBIO reported revenue of $170.44M for fiscal 2025, up 104.54% from fiscal 2024.
Does REGENXBIO pay a dividend?
REGENXBIO's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from REGENXBIO Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures